Citation
Mazanhanga, Marian T., et al. "Liquid Chromatography-tandem Mass Spectrometry Analysis of Delamanid and Its Metabolite in Human Cerebrospinal Fluid Using Protein Precipitation and On-line Solid-phase Extraction." Journal of Pharmaceutical and Biomedical Analysis, vol. 227, 2023, p. 115281.
Mazanhanga MT, Joubert A, Castel SA, et al. Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction. J Pharm Biomed Anal. 2023;227:115281.
Mazanhanga, M. T., Joubert, A., Castel, S. A., van der Merwe, M., Maartens, G., Dooley, K. E., Upton, C. M., & Wiesner, L. (2023). Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis, 227, 115281. https://doi.org/10.1016/j.jpba.2023.115281
Mazanhanga MT, et al. Liquid Chromatography-tandem Mass Spectrometry Analysis of Delamanid and Its Metabolite in Human Cerebrospinal Fluid Using Protein Precipitation and On-line Solid-phase Extraction. J Pharm Biomed Anal. 2023 Apr 1;227:115281. PubMed PMID: 36739721.
TY - JOUR
T1 - Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction.
AU - Mazanhanga,Marian T,
AU - Joubert,Anton,
AU - Castel,Sandra A,
AU - van der Merwe,Marthinus,
AU - Maartens,Gary,
AU - Dooley,Kelly E,
AU - Upton,Caryn M,
AU - Wiesner,Lubbe,
Y1 - 2023/02/03/
PY - 2022/12/19/received
PY - 2023/01/30/revised
PY - 2023/02/01/accepted
PY - 2024/04/01/pmc-release
PY - 2023/2/6/pubmed
PY - 2023/2/6/medline
PY - 2023/2/5/entrez
KW - Cerebrospinal fluid (CSF)
KW - DM-6705
KW - Delamanid
KW - Drug-resistant tuberculosis (DR-TB)
KW - LC-MS/MS
KW - On-line solid-phase extraction (SPE)
SP - 115281
EP - 115281
JF - Journal of pharmaceutical and biomedical analysis
JO - J Pharm Biomed Anal
VL - 227
N2 - The penetration of the antituberculosis drug delamanid into the central nervous system is not established. The distribution of delamanid and its major metabolite, DM-6705, into the cerebrospinal fluid requires investigation. A liquid chromatography-tandem mass spectrometry method for the quantification of delamanid and DM-6705 in human cerebrospinal fluid was developed and validated. The calibration range for both analytes was 0.300 - 30.0 ng/mL. The deuterium-labelled analogue of delamanid (delamanid-d4) and OPC-14714 were used as internal standards for delamanid and DM-6705, respectively. Samples were processed by protein precipitation followed by on-line solid-phase extraction and high-performance liquid chromatography on an Agilent 1260 HPLC system. A Phenomenex Gemini-NX C18 (5.0 µm, 50 mm × 2.0 mm) analytical column was used for on-line solid-phase extraction, and a Waters Xterra MS C18 (5.0 µm, 100 mm × 2.1 mm) analytical column for chromatographic separation using gradient elution, at a flow rate of 300 µL/min. The total run time was 7.5 min. Analytes were detected by multiple reaction monitoring on an AB Sciex 5500 triple quadrupole mass spectrometer at unit mass resolution, with electrospray ionization in the positive mode. Accuracy and precision were assessed over three independent validation batches. Extraction recoveries were more than 98% and were consistent across the analytical range. Both analytes in CSF exhibited non-specific adsorption to polypropylene tubes. The method was used to analyse cerebrospinal fluid samples from patients with pulmonary tuberculosis in an exploratory pharmacokinetic study.
SN - 1873-264X
UR - https://www.unboundmedicine.com/medline/citation/36739721/Liquid_chromatography_tandem_mass_spectrometry_analysis_of_delamanid_and_its_metabolite_in_human_cerebrospinal_fluid_using_protein_precipitation_and_on_line_solid_phase_extraction_
DB - PRIME
DP - Unbound Medicine
ER -